Policy Research Grants
Funding For:
Price Benchmarks and Limits for Biologics and Specialty Drugs
Health Care Costs & Quality
Recipient:
James Robinson, University of California, Berkeley
Grant Period:
Jan 01, 2026 - Dec 31, 2026
AMOUNT:
$50,000.00
Summary of the Project:
Medicare limits its exposure to drug prices through payment formulas and ceilings; however, private insurers do not have similar authority. This study will use claims data from Blue Cross and Blue Shield plans nationwide to develop four sets of benchmarks for assessing and limiting drug prices charged by hospitals to private insurers for complex specialty and biologic drugs, and estimate potential savings for purchasers and insurers if prices are limited to benchmarks.
Research Team:
James Robinson, University of California, Berkeley
Christopher Whaley, Brown University
Grantee Publications
March 11, 2026
Hospital Adoption and Pricing for Oncology Biosimilars
Learn MoreAuthor: James C. Robinson, PhD, Ari D. Kosorukov, BA, Christopher M. Whaley, PhD